New London

Researchers are evaluating the usability of the WearLinq eWave patch, a wearable multi-channel ECG monitoring device, in a general adult population. The study includes healthy adults as well as those with heart disease, arrhythmia, or other cardiac conditions. The goal is to understand how well participants can use this device and to monitor its wear duration and any adverse events during usage. Participants will apply the WearLinq patch continuously for 7 consecutive days in the primary study group. A smaller group of participants will be asked to use the patch for an extended period of 30 consecutive days. The patch continuously tracks cardiac rhythm by monitoring electrical activity from the chest area. During the study, participants will be monitored for how long they wear the device and for any adverse effects related to its use. Researchers will collect data on device adherence and safety outcomes over the wear periods. The total study duration for participants varies depending on whether they are in the 7-day or 30-day use groups, with all assessments focused on supportive care and device usability.